Stock Movers: Keurig Dr Pepper, Carter's, and Avidity Biosciences Discussed

Keurig Dr Pepper's Financial Outlook

• 📈 Keurig Dr Pepper (KDP) shares saw a significant increase due to revised fiscal 2025 constant currency net sales growth expectations, now projected in a high-single-digit range.
• 🤝 The company is raising $7 billion from Apollo and KKR to finance its acquisition of JDE Peet’s NV, aiming to alleviate investor concerns about increased debt.
• ☕ US coffee sales, which had previously declined for ten quarters, grew by 1.5%.
• 🏢 Keurig Dr Pepper plans to separate its beverage and coffee businesses by the end of 2026.

Carter's Financial Challenges

• 📉 Carter's (CRI) experienced a stock decline, reporting third-quarter net sales that fell short of analyst estimates.
• 💸 The company anticipates a pre-tax earnings impact of $200 million to $250 million annually due to additional tariffs.
• 🛍️ Carter's plans to close approximately 150 stores in North America over the next three years, an increase from its previous target of 100.
• 🧑‍💼 A reduction of about 15% in office-based roles, equating to roughly 300 positions, is expected to generate $35 million in annual savings starting next year.

Avidity Biosciences Acquisition

• 🚀 Avidity Biosciences (RNA) shares rallied significantly after Novartis agreed to acquire the biotechnology company for $12 billion.
• 💊 This acquisition marks Novartis' largest in over a decade and aims to bolster its portfolio with potential blockbuster treatments as generic competition looms for its current top-selling drugs.
• 🔬 Avidity is developing experimental drugs for diseases such as neuromuscular illness, with Novartis expecting two to three Avidity drugs to launch before 2030, each with multi-billion dollar sales potential.
• 🧬 As part of the deal, Avidity will separate its early-stage cardiology programs into a new entity that can be sold to a third party.